Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Using genetics to predict toxicity of cancer immunotherapy

A variant of the IL7 gene predicts the toxicity of checkpoint inhibitors in patients with cancer, via a mechanism shared with autoimmune diseases — which could inform biomarker and treatment strategies in both of these contexts.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Impact of an IL7 variant on patients with cancer.


  1. Boutros, C. et al. Nat. Rev. Clin. Oncol. 13, 473–486 (2016).

    Article  CAS  Google Scholar 

  2. Postow, M. A., Sidlow, R. & Hellmann, M. D. N. Engl. J. Med. 378, 158–168 (2018).

    Article  CAS  Google Scholar 

  3. Hua, C. et al. JAMA Dermatol. 152, 45–51 (2016).

    Article  Google Scholar 

  4. Groha, S. Nat. Med. (2022).

    Article  Google Scholar 

  5. Taylor, C. A. Nat. Med. (2022).

    Article  Google Scholar 

  6. Barata, J. T., Durum, S. K. & Seddon, B. Nat. Immunol. 20, 1584–1593 (2019).

    Article  CAS  Google Scholar 

  7. Dooms, H. J. Autoimmun. 45, 40–48 (2013).

    Article  CAS  Google Scholar 

  8. Rivière, E. et al. Arthritis Rheumatol. 73, 631–640 (2021).

    Article  Google Scholar 

  9. Pachynski, R. K. et al. J. Immunother. Cancer 9, e002903 (2021).

    Article  Google Scholar 

  10. Murakami, S. & Jaffrey, S. R. Mol. Cell 82, 2236–2251 (2022).

    Article  CAS  Google Scholar 

  11. Childs-Disney, J. L. et al. Nat. Rev. Drug Discov. 21, 736–762 (2022).

    Article  CAS  Google Scholar 

  12. Stanley, R. F. & Abdel-Wahab, O. Nat. Cancer 3, 536–546 (2022).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Caroline Robert.

Ethics declarations

Competing interests

C.R. is an occasional consultant for Roche, BMS, MSD, Sanofi, AstraZeneca, Pierre Fabre, Novartis and scientific co-Founder of Ribonexus; S.V. is scientific co-founder of Ribonexus Xavier Mariette is an occasional consultant for AstraZeneca, Novartis, BMS, Galapagos, Pfizer, GSK.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Robert, C., Vagner, S. & Mariette, X. Using genetics to predict toxicity of cancer immunotherapy. Nat Med 28, 2471–2472 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing